SUPERNUS PHARMACEUTICALS INC (SUPN)
NASDAQ • Healthcare
Last close at August 10, 2026 at 20:00 UTC
Fundamentals Charts
About SUPERNUS PHARMACEUTICALS INC
Supernus Pharmaceuticals, Inc. develops and commercializes central nervous system medicines in the healthcare sector and trades on the NASDAQ under SUPN. Its portfolio spans treatments for epilepsy, ADHD, Parkinson's disease, and other neurologic conditions, and the company recorded $719.0 million of revenue in FY2025.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
SUPERNUS PHARMACEUTICALS INC's Technical Indicators Summary
SUPN presents a constructive short-to-intermediate picture with price trading above several short-term moving averages even as the 100- and 200-day averages remain higher, producing mixed timeframe signals. Momentum is mildly positive and the RSI is neutral around the mid-50s, while ADX near 22 indicates only modest trend strength; ATR shows above-average volatility. Volume metrics are not supportive, and the classic pivot sits just above the current price, marking a nearby resistance zone. Technical takeaway: Buy — short- to medium-term moving averages support a constructive bias.
| Indicator | Value |
|---|---|
RSI (14) | 51.47 |
Stochastic %K (14, 3, 3) | 45.86 |
CCI (20) | 17.94 |
WPR (14) | -55.02 |
Momentum (10) | 0.09 |
MFI | 56.58 |
MACD Level (12, 26) | -0.12 |
Bollinger Bands | $44.36 - $49.18 |
ATR (14) | $2.21 (4.70%) |
ADX (14) | 21.65 |
OBV | 13,528,482 |
Classic Pivot Point | $47.32 |
Fibonacci Pivot Point | $47.32 |
Simple Moving Averages | $46.18 - $48.90(5 indicators) |
Exponential Moving Averages | $46.54 - $47.85(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
A gentle pullback defined the last session for SUPN, which slipped -1.20% by the close. SUPN's planned all-stock merger with Indivior could unlock upside as deal talks advance.
Trading Volume
Below 10d avg (1.5M)
707.8K
vs S&P 500 Today
Underperforming Market
-1.14%
52-Week Position
Lower range
34.3%
Updated: August 11, 2026 at 12:29 UTC